200 related articles for article (PubMed ID: 25526234)
41. [Osteoporosis treatment can be discontinued based on an individual assessment].
Eiken PA; Abrahamsen B
Ugeskr Laeger; 2017 Jan; 179(2):. PubMed ID: 28074765
[TBL] [Abstract][Full Text] [Related]
42. Current and future treatments of secondary osteoporosis.
Soriano R; Herrera S; Nogués X; Diez-Perez A
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):885-94. PubMed ID: 25432359
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcome of weekly bisphosphonates.
Rizzoli R
Clin Orthop Relat Res; 2006 Feb; 443():61-5. PubMed ID: 16462427
[TBL] [Abstract][Full Text] [Related]
44. Compliance with treatment in osteoporosis patients--an ongoing problem.
Sambrook P
Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
[TBL] [Abstract][Full Text] [Related]
45. [Measurement of bone mineral density is unnecessary for monitoring of bisphosphonate treatment].
Nishida A; Ito M
Clin Calcium; 2011 Jan; 21(1):120-3. PubMed ID: 21187605
[TBL] [Abstract][Full Text] [Related]
46. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens G; Jackson R; Lewiecki EM
Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
[TBL] [Abstract][Full Text] [Related]
47. [Bisphosphonates first-line pharmacological treatment].
Wallander M; Ljunggren Ö; Lorentzon M
Lakartidningen; 2016 Nov; 113():. PubMed ID: 27824394
[No Abstract] [Full Text] [Related]
48. MANAGEMENT OF ENDOCRINE DISEASE: Treatment breaks in long-term management of osteoporosis.
Langdahl BL
Eur J Endocrinol; 2019 Jan; 180(1):R29-R35. PubMed ID: 30444721
[TBL] [Abstract][Full Text] [Related]
49. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation.
Imai K
Clin Interv Aging; 2013; 8():681-8. PubMed ID: 23766643
[TBL] [Abstract][Full Text] [Related]
50. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
Curtis JR; Xi J; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
Med Care; 2009 Mar; 47(3):334-41. PubMed ID: 19194337
[TBL] [Abstract][Full Text] [Related]
51. Review of adherence to medications for the treatment of osteoporosis.
Gold DT; Silverman S
Curr Osteoporos Rep; 2006 Mar; 4(1):21-7. PubMed ID: 16527004
[TBL] [Abstract][Full Text] [Related]
52. [Bisphosphonate use and related pharmaceutical issues II].
Veszelyné Kotan E; Mészáros Á
Acta Pharm Hung; 2016; 86(1):23-34. PubMed ID: 27295874
[TBL] [Abstract][Full Text] [Related]
53. Compliance and persistence with osteoporosis therapies.
Silverman SL; Gold DT
Curr Rheumatol Rep; 2008 Apr; 10(2):118-22. PubMed ID: 18460266
[TBL] [Abstract][Full Text] [Related]
54. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis.
Fontalis A; Eastell R
Bone; 2020 Jul; 136():115336. PubMed ID: 32234415
[TBL] [Abstract][Full Text] [Related]
55. [Adherence to treatment of osteoporosis: an open question].
Varenna M; Sinigaglia L
Reumatismo; 2009; 61(1):4-9. PubMed ID: 19370181
[TBL] [Abstract][Full Text] [Related]
56. Why do women reject bisphosphonates for osteoporosis? A videographic study.
Scoville EA; Ponce de Leon Lovaton P; Shah ND; Pencille LJ; Montori VM
PLoS One; 2011 Apr; 6(4):e18468. PubMed ID: 21533288
[TBL] [Abstract][Full Text] [Related]
57. Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate.
Simonelli C; Burke MS
Curr Med Res Opin; 2006 Jun; 22(6):1101-8. PubMed ID: 16846543
[TBL] [Abstract][Full Text] [Related]
58. The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis.
Gao Y; Liu X; Gu Y; Song D; Ding M; Liao L; Wang J; Ni J; He G
Front Endocrinol (Lausanne); 2021; 12():688269. PubMed ID: 34526966
[TBL] [Abstract][Full Text] [Related]
59. Adherence to treatment of osteoporosis: a need for study.
Lekkerkerker F; Kanis JA; Alsayed N; Bouvenot G; Burlet N; Cahall D; Chines A; Delmas P; Dreiser RL; Ethgen D; Hughes N; Kaufman JM; Korte S; Kreutz G; Laslop A; Mitlak B; Rabenda V; Rizzoli R; Santora A; Schimmer R; Tsouderos Y; Viethel P; Reginster JY;
Osteoporos Int; 2007 Oct; 18(10):1311-7. PubMed ID: 17585359
[TBL] [Abstract][Full Text] [Related]
60. Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study.
Swart KMA; van Vilsteren M; van Hout W; Draak E; van der Zwaard BC; van der Horst HE; Hugtenburg JG; Elders PJM
BMC Fam Pract; 2018 Aug; 19(1):141. PubMed ID: 30139341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
